EDN1 and Alzheimer disease: Thus, one might speculate that the elevated serum β-endorphin level often detected in AD patients might be the consequence and the final common effector of the pathological activity of IL-31, CRH, and/or the TLR3–ET-1 axes, at least in a subset of AD patients.